作者: Fariz Nurwidya , Fumiyuki Takahashi , Akiko Murakami , Kazuhisa Takahashi
DOI: 10.3969/J.ISSN.2095-3941.2012.01.003
关键词:
摘要: One of the most important pathways in non-small cell lung cancer (NSCLC) is epidermal growth factor receptor (EGFR) pathway. This pathway affects several crucial processes tumor development and progression, including proliferation, apoptosis regulation, angiogenesis, metastatic invasion. Targeting EGFR currently being intensely explored. We are witnessing a number potential molecular-inhibiting treatments for application clinical oncology. In last decade, tyrosine kinase (TK) domain was identified NSCLC patients, it has responded very well with dramatic improvement to TK inhibitors such gefitinib erlotinib. Unfortunately, there were primary and/or secondary resistance these treatments, as shown by trials. Subsequent molecular biology studies provided some explanations drug phenomenon. The mechanisms need be clarified. An in-depth understanding targeted-therapy may help us explore new strategies overcoming or reversing future treatment.